 Aeterna Zentaris Inc. AEZS AEZS.TO the Company, a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has entered into an exclusive distribution and related quality agreement the Agreement with Megapharm Ltd. Megapharm, a leading Israel-based biopharmaceutical company, for the commercialization in Israel and the Palestinian Authority of macimorelin, Aeterna Zentaris orally available ghrelin agonist to be used in the diagnosis of patients with adult growth hormone deficiency AGHD and child-onset growth hormone deficiency CGHD. Under the terms of the agreement, Megapharm will be responsible for obtaining registration to market macimorelin in Israel and the Palestinian Authority, while Aeterna Zentaris will be responsible for manufacturing, product supply, quality assurance and control, regulatory support, and maintenance of IP. 